Datum Källa Rubrik Typ Alternativ
2021-03-02 Genovis Genovis AB: Proposal to expand the Genovis Board of Directors at 2021 AGM Pressreleaser Ladda ner | Visa Stäng
2021-03-02 Genovis Genovis AB: Genovis styrelse föreslås utökas vid årsstämman 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-11 Genovis Genovis AB: Bokslutskommuniké 2020 Rapporter Ladda ner | Visa Stäng
2021-02-11 Genovis Genovis AB: Year-end Report January - December 2020 Rapporter Ladda ner | Visa Stäng
2020-12-10 Genovis Genovis AB: Genovis and Glykos partner to enable new ADC platform Pressreleaser Ladda ner | Visa Stäng
2020-12-10 Genovis Genovis AB: Genovis inleder samarbete med Glykos och erbjuder ny plattform för ADC Pressreleaser Ladda ner | Visa Stäng
2020-11-05 Genovis Genovis AB: Delårsrapport för det tredje kvartalet 2020 Rapporter Ladda ner | Visa Stäng
2020-11-05 Genovis Genovis AB: Report for the third quarter of 2020 Rapporter Ladda ner | Visa Stäng
Rapporter | 5 Nov 2020 | Genovis

Genovis AB: Report for the third quarter of 2020

July – September in brief

  • Net sales totaled SEK 14,216 (24,279) thousand. Adjusted for acquired sales, bioprocess sales in 2019 and changes in exchange rates, growth rose by 18%.
  • Gross profit totaled SEK 15,487 (20,814) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 3,262 (7,987) thousand.
  • Operating result totaled SEK 1,715 (7,019) thousand.
  • Comprehensive income was SEK 662 (7,473) thousand.
  • Comprehensive income per share, basic and diluted, totaled SEK 0.01 (0.12).
  • Cash flow from operating activities was SEK 1,191 (7,448) thousand.
  • Cash and cash equivalents at the end of the period totaled SEK 46,231 (15,303) thousand.

January – September in brief

  • Net sales totaled SEK 41,180 (47,719) thousand. Adjusted for acquired sales, bioprocess sales in 2019 and changes in exchange rates, growth rose by 14%.
  • Gross profit totaled SEK 39,609 (44,123) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,377 (13,072) thousand was negatively impacted by non-recurring items for acquisitions and restructuring costs of SEK 2.5 million.
  • Operating result totaled SEK -1,465 (profit: 10,589) thousand.
  • Comprehensive income totaled SEK -4,376 (10,444) thousand.
  • Comprehensive income per share, basic and diluted, totaled SEK -0.07 (0.17).
  • During the year Genovis acquired all shares of QED Bioscience Inc. Total cost of the acquisition, including transaction costs, is SEK 20 million
  • In the first quarter Genovis raised SEK 50 million for the Company before issue expenses in a directed share issue.

 

Comments from Fredrik Olsson, Chief Executive Officer

In the third quarter, organic growth for the core business for enzymes within Analytics was 18%, which is a doubling compared with the second quarter this year. Organic growth for the nine-month period for the core business was 14%.

We have periodically experienced challenges in various geographic markets as a result of local restrictions associated with the pandemic. Customers have reduced the number of employees working at the same time in laboratories to reduce the risk of spread of infection, which negatively affects productivity and the number of analyses carried out. Nevertheless, the revenue in our core business grew and we remain strongly convinced that the markets will improve over time when the restrictions can be reduced.

QED, which sells antibodies for the diagnostics industry, has been impacted by the general reduction of tests conducted within health services since fewer people seek care that is not related to the ongoing pandemic. However, at the beginning of the fourth quarter we have seen customer activities resume in QED’s antibody business as the diagnostics market recovers and more customers return to laboratories within industry and academia.

As it has become more apparent that our normal marketing activities, such as scientific conferences, trade shows and customer encounters, have all been postponed, we have transitioned to investing in our customer support systems and electronic marketing channels. The basic strategy remains the same – scientific communication with solutions and unique products for our customers within the global biopharma industry. We have streamlined the work in our electronic channels to prioritize business opportunities and new sales. With these initiatives, the inflow of new customers has continued and our customer base has continued to grow during the quarter.

We have not received any government relief, nor have we furloughed any employees, despite the uncertain situation over the past six months Instead, we have chosen to lean forward and focus our resources on bold initiatives for the future.

A strong focus on our product development projects has culminated in three product launches, two of which are completely new enzymes for analysis within the biopharma industry. We have maintained good momentum in our development pipeline and intend to launch additional products at the end of the year in order to be even better equipped for 2021.

We have also worked intensively to broaden and strengthen our industrial partnerships. This is a key component of our strategy to build customer value by offering our customers several automated workflows with our products.

Our efforts to ensure production capacity in both the short term and the long term are proceeding according to plan: in the short-term through skilled subcontractors, and in the long term through planned investments in our own infrastructure and capacity to meet our anticipated growth over time.

Despite the continued uncertainty about market conditions in the short term as a result of the pandemic, my assessment is that Genovis’ business opportunities moving forward will be strengthened as a result of initiatives with an increased focus on research, diagnostics and biological drugs in the wake of the pandemic.

I am extremely impressed by the innovation and resilience of my employees as they cope with these new circumstances, which have led to the continued strong organic growth of the core business in a challenging business climate.

Although the external situation is difficult to assess in the short term, I am convinced that our innovative efforts and business model will enable us to fulfill our high ambitions with continued strong growth over time.

2020-08-13 Genovis Genovis AB: Halvårsrapport januari - juni 2020 Rapporter Ladda ner | Visa Stäng
2020-08-13 Genovis Genovis AB: Half-Yearly Report January - June 2020 Rapporter Ladda ner | Visa Stäng
2020-05-05 Genovis Communiqué from Genovis AB (publ) Annual General Meeting May 5, 2020 Pressreleaser Ladda ner | Visa Stäng
2020-05-05 Genovis Kommuniké från Årsstämman i Genovis AB (publ) den 5 maj 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-29 Genovis Genovis AB: Genovis acquires all shares in QED Bioscience Inc., San Diego, CA, USA Pressreleaser Ladda ner | Visa Stäng
2020-04-29 Genovis Genovis AB: Genovis förvärvar samtliga aktier i QED Bioscience Inc. USA Pressreleaser Ladda ner | Visa Stäng
2020-04-29 Genovis Genovis AB: Interim Report January - March 2020 Rapporter Ladda ner | Visa Stäng
2020-04-29 Genovis Genovis AB: Kvartalsrapport januari - mars 2020 Rapporter Ladda ner | Visa Stäng
2020-04-14 Genovis Genovis AB publish Annual Report 2019 Pressreleaser Ladda ner | Visa Stäng
2020-04-14 Genovis Genovis AB: Genovis årsredovisning för 2019 publicerad Pressreleaser Ladda ner | Visa Stäng
2020-04-07 Genovis Genovis AB: Redeye: Genovis - Paradigm Play Pressreleaser Visa Stäng
2020-03-30 Genovis Genovis AB: NOTICE OF ANNUAL GENERAL MEETING IN GENOVIS AB Pressreleaser Ladda ner | Visa Stäng
2020-03-30 Genovis Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2020 Pressreleaser Ladda ner | Visa Stäng
2020-03-23 Genovis Genovis AB: Nomination Committee proposes Torben Jørgensen for new chairman of Genovis Pressreleaser Ladda ner | Visa Stäng
2020-03-23 Genovis Genovis AB: Valberedningen föreslår Torben Jørgensen till ny ordförande i Genovis Pressreleaser Ladda ner | Visa Stäng
2020-02-21 Genovis Genovis AB: Redeye: Genovis - Slutar aldrig att leverera Pressreleaser Visa Stäng
2020-02-20 Genovis Genovis AB: Genovis intends to acquire QED Bioscience and conduct a rights issue of SEK 50 million Pressreleaser Ladda ner | Visa Stäng
2020-02-20 Genovis Genovis AB: Genovis avser att förvärva QED Bioscience och genomför riktad emission om ca 50 MSEK Pressreleaser Ladda ner | Visa Stäng
2020-02-05 Genovis Genovis AB: Bokslutsrapport januari - december 2019 Rapporter Ladda ner | Visa Stäng
2020-02-05 Genovis Genovis AB: Year-end Report January - December 2019 Rapporter Ladda ner | Visa Stäng
2020-01-31 Genovis Genovis AB (publ) to publish 2020 reports ahead of schedule Pressreleaser Ladda ner | Visa Stäng
2020-01-31 Genovis Genovis AB (publ) tidigarelägger samtliga finansiella rapporter 2020 Pressreleaser Ladda ner | Visa Stäng
2020-01-21 Genovis Genovis AB: BioStock: Genovis nya CFO ser ljust på framtiden Pressreleaser Visa Stäng
2019-12-20 Genovis Genovis AB: COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING FOR GENOVIS AB (PUBL) DECEMBER 20, 2019 Pressreleaser Ladda ner | Visa Stäng
2019-12-20 Genovis Genovis AB: KOMMUNIKÉ FRÅN EXTRA BOLAGSTÄMMAN I GENOVIS AB (PUBL) DEN 20 DECEMBER 2019 Pressreleaser Ladda ner | Visa Stäng
2019-12-10 Genovis Genovis AB: Genovis launches Immobilized SialEXO[®]for efficient biopharmaceutical sample preparation Pressreleaser Ladda ner | Visa Stäng
2019-12-10 Genovis Genovis AB: Genovis lanserar Immobilized SialEXO[ ]för effektivare provbearbetning av biologiska läkemedel Pressreleaser Ladda ner | Visa Stäng
2019-12-04 Genovis Genovis AB (publ) announces Extraordinary General Meeting Pressreleaser Ladda ner | Visa Stäng
2019-12-04 Genovis Genovis AB (publ) kallar till extra bolagsstämma Pressreleaser Ladda ner | Visa Stäng
2019-11-28 Genovis Genovis AB: BioStock studiointervju: Genovis kommenterar sin Q3 rapport Pressreleaser Visa Stäng
2019-11-27 Genovis Genovis AB: Redeye: Genovis - När lugnet har lagt sig fortsätter (tillväxt-)resan Pressreleaser Visa Stäng
2019-11-21 Genovis Genovis AB: Interim Report January-September 2019 Rapporter Ladda ner | Visa Stäng
2019-11-21 Genovis Genovis AB: Delårsrapport januari - september 2019 Rapporter Ladda ner | Visa Stäng
2019-09-12 Genovis Genovis AB: Redeye: Genovis - Ett potentiellt game changer case Pressreleaser Visa Stäng
2019-08-28 Genovis Genovis AB: Half-Yearly Report January - June 2019 Rapporter Ladda ner | Visa Stäng
2019-08-28 Genovis Genovis AB: Halvårsrapport januari - juni 2019 Rapporter Ladda ner | Visa Stäng
2019-08-19 Genovis Genovis AB: Genovis receives order worth about SEK 13 million Pressreleaser Ladda ner | Visa Stäng
2019-08-19 Genovis Genovis AB: Genovis erhåller order värd ca 13 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2018-11-27 Genovis Interim Report January - September 2018 Rapporter Ladda ner | Visa Stäng
2018-11-27 Genovis Delårsrapport januari - september 2018 Rapporter Ladda ner | Visa Stäng
2018-11-08 Genovis Genovis certified to ISO 9001:2015 Pressreleaser Ladda ner | Visa Stäng
2018-11-08 Genovis Genovis certifierat enligt ISO 9001:2015 Pressreleaser Ladda ner | Visa Stäng
2018-09-18 Genovis Genovis launches FabRICATOR®-HPLC for automated antibody analysis Pressreleaser Ladda ner | Visa Stäng
2018-09-18 Genovis Genovis lanserar FabRICATOR®-HPLC för automatiserad antikroppsanalys Pressreleaser Ladda ner | Visa Stäng
2018-09-04 Genovis Redeye: Genovis - Ett tillväxtcase med lönsamhet runt hörnet Pressreleaser Visa Stäng
2018-08-28 Genovis Half-Yearly Report January - June 2018 Rapporter Ladda ner | Visa Stäng
2018-08-28 Genovis Halvårsrapport januari - juni 2018 Rapporter Ladda ner | Visa Stäng
2018-07-05 Genovis Genovis further expands marketing organization Pressreleaser Ladda ner | Visa Stäng
2018-07-05 Genovis Genovis expanderar marknadsorganisationen ytterligare Pressreleaser Ladda ner | Visa Stäng
2018-05-17 Genovis Communiqué from Genovis AB (publ) Annual General Meeting May 17, 2018 Pressreleaser Ladda ner | Visa Stäng
2018-05-17 Genovis Kommuniké från Årsstämman i Genovis AB (publ) den 17 maj 2018 Pressreleaser Ladda ner | Visa Stäng
2018-05-15 Genovis Interim Report January - March 2018 Rapporter Ladda ner | Visa Stäng
2018-05-15 Genovis Kvartalsrapport januari - mars 2018 Rapporter Ladda ner | Visa Stäng
2018-04-29 Genovis Genovis carries out directed share issue to raise SEK 10.1 million for the company Pressreleaser Ladda ner | Visa Stäng
2018-04-29 Genovis Genovis genomför en riktad emission som tillför bolaget ca 10,1 MSEK Pressreleaser Ladda ner | Visa Stäng
2018-04-26 Genovis Genovis launches GlycOCATCH™ for purification of O-glycosylated proteins Pressreleaser Ladda ner | Visa Stäng
2018-04-26 Genovis Genovis lanserar GlycOCATCH™ för upprening av O-glykosylerade proteiner Pressreleaser Ladda ner | Visa Stäng
2018-04-24 Genovis Genovis strengthens its marketing organization in the US Pressreleaser Ladda ner | Visa Stäng
2018-04-24 Genovis Genovis förstärker sin marknadsorganisation i USA Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Genovis Proposal to expand the Genovis Board of Directors at 2018 Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Genovis Genovis styrelse föreslås utökas vid årsstämman 2018 Pressreleaser Ladda ner | Visa Stäng
2018-04-06 Genovis Genovis signs distribution agreement for South Korean market Pressreleaser Ladda ner | Visa Stäng
2018-04-06 Genovis Genovis tecknar distributionsavtal för den sydkoreanska marknaden Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Genovis NOTICE OF ANNUAL GENERAL MEETING IN GENOVIS AB Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Genovis KALLELSE TILL ÅRSSTÄMMA I GENOVIS AB Pressreleaser Ladda ner | Visa Stäng
2018-03-22 Genovis Redeye: Genovis - Positiva signaler inför 2018 Pressreleaser Visa Stäng
2018-02-28 Genovis Year-end Report January - December 2017 Rapporter Ladda ner | Visa Stäng
2018-02-28 Genovis Bokslutsrapport januari - december 2017 Rapporter Ladda ner | Visa Stäng
2018-02-14 Genovis Genovis AB (publ) postpone publication of the Year-end Report 2017 Pressreleaser Ladda ner | Visa Stäng
2018-02-14 Genovis Ändrat datum för Bokslutsrapporten januari-december 2017 i Genovis AB (publ) Pressreleaser Ladda ner | Visa Stäng
2018-01-22 Genovis Redeye: Genovis - Marknadsinsatser symboliserade Q3 Pressreleaser Visa Stäng
2017-12-08 Genovis Genovis signs distribution agreement in India Pressreleaser Ladda ner | Visa Stäng
2017-12-08 Genovis Genovis tecknar distributionsavtal i Indien Pressreleaser Ladda ner | Visa Stäng
2017-11-27 Genovis Interim Report January - September 2017 Rapporter Ladda ner | Visa Stäng
2017-11-27 Genovis Delårsrapport januari - september 2017 Rapporter Ladda ner | Visa Stäng
2017-11-07 Genovis Genovis signs distribution agreement with Shanghai Titan Scientific Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-11-07 Genovis Genovis tecknar distributionsavtal med Shanghai Titan Scientific Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-10-11 Genovis Redeye: Genovis - Fokus på Asien och nya produkter Pressreleaser Visa Stäng
2017-09-18 Genovis Genovis signs distribution agreement with Chinese Beijing Zhongyuan Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-09-18 Genovis Genovis signs distribution agreement with Chinese Beijing Zhongyuan Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-09-18 Genovis Genovis tecknar distributionsavtal med kinesiska Beijing Zhongyuan Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-09-18 Genovis Genovis tecknar distributionsavtal med kinesiska Beijing Zhongyuan Ltd. Pressreleaser Ladda ner | Visa Stäng
2017-08-28 Genovis Half-Yearly Report January - June 2017 Rapporter Ladda ner | Visa Stäng
2017-08-28 Genovis Halvårsrapport januari - juni 2017 Rapporter Ladda ner | Visa Stäng
2017-06-09 Genovis Redeye: Genovis - Klinisk produktion nästa födkrok Pressreleaser Visa Stäng
2017-05-30 Genovis Genovis expands its product portfolio and launches three products for glycan analysis Pressreleaser Ladda ner | Visa Stäng
2017-05-30 Genovis Genovis utökar produktportföljen och lanserar tre produkter för glykananalys Pressreleaser Ladda ner | Visa Stäng
2017-05-23 Genovis Analysguiden: Nya lanseringar i fokus Pressreleaser Visa Stäng
2017-05-12 Genovis Communiqué from Genovis AB (publ) Annual General Meeting May 11, 2017 Pressreleaser Ladda ner | Visa Stäng
2017-05-12 Genovis Kommuniké från Årsstämman i Genovis AB (publ) den 11 maj 2017 Pressreleaser Ladda ner | Visa Stäng
2017-05-08 Genovis Interim report January - March 2017 Rapporter Ladda ner | Visa Stäng
2017-05-08 Genovis Kvartalsrapport januari - mars 2017 Rapporter Ladda ner | Visa Stäng
2017-05-02 Genovis Genovis expands its product portfolio and launches FabALACTICA™ Pressreleaser Ladda ner | Visa Stäng
2017-05-02 Genovis Genovis utökar produktportföljen och lanserar FabALACTICA™ Pressreleaser Ladda ner | Visa Stäng
2017-04-24 Genovis Redeye: Tillväxt till attraktivt pris i Genovis Pressreleaser Visa Stäng
2017-04-20 Genovis Genovis AB publish Annual Report 2016 Rapporter Ladda ner | Visa Stäng
2017-04-20 Genovis Genovis AB publicerar årsredovisning 2016 Rapporter Ladda ner | Visa Stäng
2017-04-10 Genovis NOTICE OF ANNUAL GENERAL MEETING IN GENOVIS AB Pressreleaser Ladda ner | Visa Stäng
2017-04-10 Genovis KALLELSE TILL ÅRSSTÄMMA I GENOVIS AB Pressreleaser Ladda ner | Visa Stäng
2017-04-10 Genovis Genovis carries out directed share issue to raise SEK 11.5 million for the company Pressreleaser Ladda ner | Visa Stäng
2017-04-10 Genovis Genovis genomför en riktad emission som tillför bolaget 11,5 MSEK Pressreleaser Ladda ner | Visa Stäng
2017-04-04 Genovis Genovis AB initiates sales of GlyCLICK™ Pressreleaser Ladda ner | Visa Stäng
2017-04-04 Genovis Genovis AB inleder försäljning av GlyCLICK™ Pressreleaser Ladda ner | Visa Stäng
2017-02-27 Genovis YEAR-END REPORT JANUARY-DECEMBER 2016 Rapporter Ladda ner | Visa Stäng
2017-02-27 Genovis BOKSLUTSKOMMUNIKÉ JANUARI - DECEMBER 2016 Rapporter Ladda ner | Visa Stäng
2017-02-16 Genovis Analysguiden: Bra utsikter syns i kursen Pressreleaser Visa Stäng
2017-02-10 Genovis Redeye - Genovis fortsätter på rätt spår Pressreleaser Visa Stäng

Kommande händelser

8 May 2017 | Kvartalsrapport 2017-Q1
11 May 2017 | Årsstämma 2016
12 May 2017 | Årligutdelning 2016
28 Aug 2017 | Kvartalsrapport 2017-Q2
27 Nov 2017 | Kvartalsrapport 2017-Q3
26 Feb 2018 | Bokslutskommuniké 2017
28 Feb 2018 | Bokslutskommuniké 2017
15 May 2018 | Kvartalsrapport 2018-Q1
17 May 2018 | Årsstämma 2017
18 May 2018 | Årligutdelning
28 Aug 2018 | Kvartalsrapport 2018-Q2
27 Nov 2018 | Kvartalsrapport 2018-Q3
26 Feb 2019 | Bokslutskommuniké 2018
8 May 2019 | Kvartalsrapport 2019-Q1
23 May 2019 | Årsstämma 2018
24 May 2019 | Årligutdelning
28 Aug 2019 | Kvartalsrapport 2019-Q2
5 Feb 2020 | Bokslutskommuniké 2019
26 Feb 2020 | Bokslutskommuniké 2019
29 Apr 2020 | Kvartalsrapport 2020-Q1
5 May 2020 | Årsstämma 2019
6 May 2020 | Årligutdelning
7 May 2020 | Kvartalsrapport 2020-Q1
13 Aug 2020 | Kvartalsrapport 2020-Q2
20 Aug 2020 | Kvartalsrapport 2020-Q2
5 Nov 2020 | Kvartalsrapport 2020-Q3
10 Nov 2020 | Kvartalsrapport 2020-Q3
11 Feb 2021 | Bokslutskommuniké 2020
29 Apr 2021 | Kvartalsrapport 2021-Q1
20 May 2021 | Årsstämma 2020
21 May 2021 | Årligutdelning
12 Aug 2021 | Kvartalsrapport 2021-Q2
9 Nov 2021 | Kvartalsrapport 2021-Q3
11 Nov 2021 | Kvartalsrapport 2021-Q3

ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner